Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AYTU

AYTU - Aytu BioScience Inc Stock Price, Fair Value and News

3.11USD-0.17 (-5.18%)Delayed as of 21 Feb 2024, 01:35 pm ET
Watchlist

Market Summary

USD3.11-0.17
Delayedas of 21 Feb 2024, 01:35 pm
-5.18%

AYTU Stock Price

View Fullscreen

AYTU RSI Chart

AYTU Valuation

Market Cap

18.3M

Price/Earnings (Trailing)

-1.02

Price/Sales (Trailing)

0.19

EV/EBITDA

-3.06

Price/Free Cashflow

2.97

AYTU Price/Sales (Trailing)

AYTU Profitability

Operating Margin

59.54%

EBT Margin

-17.43%

Return on Equity

-54.72%

Return on Assets

-13.7%

Free Cashflow Yield

33.73%

AYTU Fundamentals

AYTU Revenue

Revenue (TTM)

98.5M

Rev. Growth (Yr)

-12.73%

Rev. Growth (Qtr)

3.78%

AYTU Earnings

Earnings (TTM)

-18.0M

Earnings Growth (Yr)

97.01%

Earnings Growth (Qtr)

97.54%

Breaking Down AYTU Revenue

52 Week Range

1.383.28
(Low)(High)

Last 7 days

10.5%

Last 30 days

23.8%

Last 90 days

38.4%

Trailing 12 Months

-1.5%

How does AYTU drawdown profile look like?

AYTU Financial Health

Current Ratio

1.11

Debt/Equity

0.46

Debt/Cashflow

0.41

AYTU Investor Care

Shares Dilution (1Y)

55.81%

Diluted EPS (TTM)

-6.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023104.1M107.4M101.8M98.5M
202292.7M96.7M102.4M105.6M
202157.0M65.6M74.0M82.0M
202014.5M27.6M39.7M51.7M
20196.5M7.3M7.3M8.7M
20183.6M3.7M4.0M4.8M
20173.3M3.3M3.3M3.4M
20161.8M2.6M2.8M3.1M
2015110.2K261.8K721.6K1.2M
201434.4K50.8K76.7K92.5K
201333.6K41.8K18.1K26.2K
20120017.2K25.4K
20110000
20100000

Tracking the Latest Insider Buys and Sells of Aytu BioScience Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 31, 2023
pyszczymuka greg
acquired
-
-
209
chief commercial officer
Sep 30, 2023
pyszczymuka greg
acquired
-
-
208
chief commercial officer
Aug 16, 2023
jain abhinav
acquired
-
-
6,500
-
Aug 11, 2023
jain abhinav
acquired
-
-
1,500
-
Aug 11, 2023
liu vivian h
acquired
-
-
1,500
-
Aug 11, 2023
dockery carl
acquired
-
-
1,500
-
Aug 11, 2023
donofrio john jr.
acquired
-
-
1,500
-
Jun 30, 2023
pyszczymuka greg
acquired
-
-
208
chief commerical officer
Jun 16, 2023
pyszczymuka greg
bought
22,428
1.869
12,000
chief commerical officer
Jun 14, 2023
disbrow joshua r.
bought
26,079
1.8628
14,000
chief executive officer

1–10 of 50

Which funds bought or sold AYTU recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
Nantahala Capital Management, LLC
added
100
3,238,700
6,173,090
0.18%
Feb 14, 2024
GROUP ONE TRADING, L.P.
unchanged
-
5.00
105
-%
Feb 14, 2024
VANGUARD GROUP INC
added
110
42,366
77,393
-%
Feb 14, 2024
Royal Bank of Canada
added
2,283
10,000
10,000
-%
Feb 13, 2024
GEODE CAPITAL MANAGEMENT, LLC
added
99.85
49,204
93,882
-%
Feb 13, 2024
ACADIAN ASSET MANAGEMENT LLC
reduced
-35.12
-18,000
41,000
-%
Feb 13, 2024
MORGAN STANLEY
unchanged
-
195
3,975
-%
Feb 13, 2024
NORTHERN TRUST CORP
unchanged
-
2,040
41,373
-%
Feb 13, 2024
FMR LLC
reduced
-75.00
-8.00
3.00
-%

1–10 of 27

Are Funds Buying or Selling AYTU?

Are funds buying AYTU calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AYTU
No. of Funds

Unveiling Aytu BioScience Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
stonepine capital management, llc
9.99%
565,484
SC 13G/A
Jun 16, 2023
stonepine capital management, llc
9.99%
563,842
SC 13G
Jun 16, 2023
nantahala capital management, llc
19.7%
1,086,812
SC 13D/A
May 26, 2023
nantahala capital management, llc
7.2%
271,595
SC 13D
Feb 14, 2023
cvi investments, inc.
4.9%
3,278,844
SC 13G/A
Aug 15, 2022
cvi investments, inc.
5.6%
3,400,000
SC 13G
Feb 11, 2022
stonepine capital management, llc
0%
0
SC 13G/A
Sep 01, 2021
armistice capital, llc
4.9%
-
SC 13D/A
Aug 31, 2021
armistice capital, llc
5.3%
-
SC 13D/A
Mar 26, 2021
integrated core strategies (us) llc
0.0%
2,446
SC 13G

Recent SEC filings of Aytu BioScience Inc

View All Filings
Date Filed Form Type Document
Feb 14, 2024
8-K
Current Report
Feb 14, 2024
10-Q
Quarterly Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 02, 2024
4
Insider Trading
Nov 17, 2023
8-K
Current Report
Nov 14, 2023
8-K
Current Report
Nov 14, 2023
10-Q
Quarterly Report

Peers (Alternatives to Aytu BioScience Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
380.2B
93.0B
-3.60% -2.76%
10.82
4.09
6.46% 95.94%
155.8B
23.6B
-3.76% -37.06%
-118.38
6.6
-28.02% -113.34%
151.9B
28.2B
-7.44% 18.02%
22.62
5.39
7.09% 2.52%
89.8B
27.4B
-17.13% -16.65%
15.28
3.28
0.94% 76.21%
14.7B
15.8B
15.02% 26.90%
-26.21
0.92
6.17% 77.01%
MID-CAP
5.1B
1.6B
14.11% 18.79%
23.62
3.19
40.56% 266.27%
4.4B
4.7B
-2.94% -9.06%
-1.1K
0.94
5.74% 96.18%
3.1B
8.5B
-0.23% 18.85%
-3.26
0.37
5.11% -479.13%
2.5B
601.3M
-0.28% 70.16%
18.57
4.18
24.02% 75.17%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.93
1.91
16.26% -147.49%
24.0M
70.0M
-0.88% -54.80%
0.35
0.34
-19.54% 888.31%
21.2M
84.1M
58.23% -28.98%
-0.99
0.22
2882.68% -145.15%
17.3M
111.1M
-6.33% -18.68%
-1.08
0.16
-10.43% 84.90%
2.6M
20.0M
-35.83% -91.10%
-0.19
0.13
137.71% 66.04%

Aytu BioScience Inc News

Latest updates
Investing.com15 Feb 202408:34 pm

Aytu BioScience Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue3.8%22,93422,09930,73222,73326,27927,65527,44824,19923,12521,89723,48213,48315,14713,52014,8618,1563,1751,4401,7162,3781,795
Cost Of Revenue----9,9908,9869,62312,60611,51310,8269,44112,18313,9356,2514,0635,3011,999606376649617525
Gross Profit9.6%16,20314,78418,56412,74317,29318,03214,84212,68612,29912,45611,299-4528,8969,457-------
Costs and Expenses------------39,14820,722--12,9508,142----
Operating Expenses-15.0%13,83916,28818,43321,30124,08619,84032,05866,10723,59340,15535,37125,21414,47113,01413,21512,9508,1426,1756,2966,6766,346
  S&GA Expenses-11.4%6,5767,4227,98212,80410,56010,10210,0139,7439,6609,29712,1806,5975,7055,826-8,7709,1906,5165,1464,8965,3695,046
  R&D Expenses-13.2%5246044658561,7101,0643,2533,2824,4751,6524,7643902861831,49979.0067.0078.00175109149
EBITDA Margin58.3%-0.05*-0.11*-0.04*-0.18*-0.61*-0.68*-0.99*-1.04*-0.85*-0.93*-0.72*-0.09*-0.10*--------
Interest Expenses-40.3%8111,3599518401,45656568.007246681,68880014259.00248253539447195137195128
Income Taxes----------3.00-107-----------
Earnings Before Taxes107.5%608-8,120-2,457-7,200-6,693-701-16,089-53,291-11,551-27,958-18,739-25,460-9,525-4,306-------
EBT Margin27.5%-0.17*-0.24*-0.16*-0.29*-0.73*-0.80*-1.13*-1.20*-1.02*-1.10*-0.88*-0.24*-0.26*--------
Net Income97.5%-200-8,120-2,457-7,200-6,693-701-16,089-53,291-11,548-27,851-18,998-25,460-9,525-4,306-3,145-5,332-214-4,929-14,531-4,495-4,657
Net Income Margin24.0%-0.18*-0.24*-0.16*-0.29*-0.73*-0.80*-1.13*-1.20*-1.02*-1.11*-0.89*-0.74*-0.43*--------
Free Cashflow50.0%-100-20015,2212,9383,362-3,250-1,245-3,265-2,9722,059-45025,5502,926--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-1.2%13113313614714115013816922422826627216714115315974.0031.0035.0038.0042.00
  Current Assets1.1%71.0071.0073.0078.0071.0074.0060.0078.0088.0089.0010510093.0065.0075.0083.0018.0012.0015.0018.0022.00
    Cash Equivalents-2.3%20.0020.0023.0019.0020.0024.0019.0028.0035.0040.0050.0047.0062.0038.0048.0062.005.007.0011.0015.0018.00
  Inventory0.3%13.0013.0012.0014.0013.0013.0011.0014.0017.0016.0016.0017.007.0011.0010.004.002.001.001.002.002.00
  Net PPE------------6.000.000.000.000.000.000.000.000.000.00
  Goodwill--------9.0046.0046.0066.0038.0028.0028.0028.0024.0015.00----
Liabilities-100.0%-10197.0010696.0010293.0010811811612812854.0050.0058.0073.0057.0029.0028.0022.0023.00
  Current Liabilities-1.9%64.0065.0069.0085.0067.0073.0064.0080.0010198.0010984.0026.0022.0029.0042.0016.006.005.005.005.00
  Short Term Borrowings-15.6%1.001.002.0010.007.00-4.00--------------
  Long Term Debt0.9%15.0015.0015.0011.0015.0014.0014.0014.000.000.000.00----8.0023.00--5.005.00
Shareholder's Equity2.1%33.0032.0039.0041.0046.0048.0044.0058.0010611213814311321595.0086.0017.002.0011316.0020.00
  Retained Earnings-0.1%-312-312-304-301-294-287-287-270-217-206-178-159-133-124-120-116-111-111-106-91.86-87.36
  Additional Paid-In Capital-100.0%-344343343340336331329323318316302247215215203129114113108107
Shares Outstanding0.7%6.006.006.004.003.003.002.001.001.001.001.001.001.00--------
Float-----12.00---38.00---88.00---10.00---7.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations50.0%-100-2009,371-2,912-2,488-9,100-7,095-9,115-8,822-3,791-6,30019,700-2,924-7,983-7,76420,600-6,099-2,987-3,473-3,310-4,302
  Share Based Compensation-11.8%8209309009023,0671,1771,2301,2701,2291,5191,0891,522508455488263162165299377194
Cashflow From Investing-128.9%-174-76.00-1551.00-5.0042.00-41.00-70.00-3,051-86.00-2,426-317-30.00-9.00-45.27344-4,912-1,042-96.11-105-557
Cashflow From Financing95.4%-126-2,734-5,4042,583-1,86513,557-1,1171,5216,590-5,46411,814-6,39827,076-2,178-6,37268,1839,258-11725918,700

AYTU Income Statement

2023-12-31
Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended6 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Product revenue, net$ 22,934$ 26,279$ 45,033$ 53,934
Cost of sales6,7318,98614,04618,609
Gross profit16,20317,29330,98735,325
Operating expenses:    
Selling and marketing6,57610,56013,99820,662
General and administrative5,4398,01812,39515,340
Research and development5241,7101,1282,774
Amortization of intangible assets1,3001,1982,6062,395
Impairment expense02,60002,600
Loss from contingent consideration0750230
Total operating expenses13,83924,16130,12744,001
Income (loss) from operations2,364(6,868)860(8,676)
Other expense, net(1,179)(1,228)(1,888)(2,312)
(Loss) gain on derivative warrant liabilities(577)1,403(6,484)3,594
Income (loss) before income tax608(6,693)(7,512)(7,394)
Income tax expense82808280
Net loss$ (220)$ (6,693)$ (8,340)$ (7,394)
Basic and diluted weighted-average common shares outstanding (in shares)5,517,6703,110,3045,499,9512,817,979
Basic and diluted net loss per common share (in dollars per share)$ (0.04)$ (2.15)$ (1.52)$ (2.62)

AYTU Balance Sheet

2023-12-31
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Dec. 31, 2023
Jun. 30, 2023
Current assets:  
Cash and cash equivalents$ 19,529$ 22,985
Accounts receivable, net29,40328,937
Inventories13,00111,995
Prepaid expenses8,1058,047
Other current assets1,333868
Total current assets71,37172,832
Non-current assets:  
Property and equipment, net1,1271,815
Operating lease right-of-use assets[1]2,1332,054
Intangible assets, net55,71158,970
Other non-current assets907792
Total non-current assets59,87863,631
Total assets131,249136,463
Current liabilities:  
Accounts payable10,47313,478
Accrued liabilities43,41346,799
Short-term line of credit1,0261,563
Current portion of debt3985
Other current liabilities9,2367,090
Total current liabilities64,18769,015
Non-current liabilities:  
Debt, net of current portion14,97814,713
Derivative warrant liabilities12,8876,403
Other non-current liabilities6,3446,975
Total non-current liabilities34,20928,091
Commitments and contingencies (note 13)
Stockholders’ equity:  
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding00
Common stock, par value $.0001; 200,000,000 shares authorized; 5,567,347 and 5,517,174 shares issued and outstanding, respectively11
Additional paid-in capital345,321343,485
Accumulated deficit(312,469)(304,129)
Total stockholders’ equity32,85339,357
Total liabilities and stockholders’ equity$ 131,249$ 136,463
[1]Includes $0.2 million from the Consumer Health Segment as of December 31, 2023 and June 30, 2023.
AYTU
Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment, which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition, the company provides Karbinal ER, for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
 CEO
 WEBSITEaytubio.com
 EMPLOYEES164

Aytu BioScience Inc Frequently Asked Questions


What is the ticker symbol for Aytu BioScience Inc? What does AYTU stand for in stocks?

AYTU is the stock ticker symbol of Aytu BioScience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aytu BioScience Inc (AYTU)?

As of Tue Feb 20 2024, market cap of Aytu BioScience Inc is 18.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AYTU stock?

You can check AYTU's fair value in chart for subscribers.

What is the fair value of AYTU stock?

You can check AYTU's fair value in chart for subscribers. The fair value of Aytu BioScience Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aytu BioScience Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AYTU so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aytu BioScience Inc a good stock to buy?

The fair value guage provides a quick view whether AYTU is over valued or under valued. Whether Aytu BioScience Inc is cheap or expensive depends on the assumptions which impact Aytu BioScience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AYTU.

What is Aytu BioScience Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Feb 20 2024, AYTU's PE ratio (Price to Earnings) is -1.02 and Price to Sales (PS) ratio is 0.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AYTU PE ratio will change depending on the future growth rate expectations of investors.